US2004259110A1PendingUtilityA1

Gene PRV-1 and its use

41
Priority: Oct 23, 1998Filed: Dec 5, 2003Published: Dec 23, 2004
Est. expiryOct 23, 2018(expired)· nominal 20-yr term from priority
Inventors:Heike Pahl
A61P 7/02A61P 7/00A61P 31/04A61P 35/00A61P 7/06A61P 9/12A61P 35/02A61P 43/00A61P 9/00A61P 25/04A61P 29/00A61P 17/04A61P 13/12A61P 19/06A61K 38/00C07K 14/475C07K 14/47
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This document describes a nucleotide sequence which encodes the PRV-1 protein, and essentially comprises the sequence ID No. 1, and also a process for detecting this gene and the polypeptide encoded by this gene.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide, comprising one of the following amino acid sequences: 
 amino acids 1-437 of SEQ. ID NO.: 2;    amino acids 1-409 of SEQ. ID NO.: 2;    amino acids 22-437 of SEQ. ID NO.: 2;    amino acids 22-409 of SEQ. ID NO.: 2;    or a fragment thereof containing at least 50 amino acids.    
     
     
         2 . (Cancelled).  
     
     
         3 . (Cancelled).  
     
     
         4 . An isolated polynucleotide, comprising one of the following nucleotide sequences: 
 nucleotides 1-1600 of SEQ. ID NO.: 1;    nucleotides 36-1346 of SEQ. ID NO.: 1;    nucleotides 36-1262 of SEQ. ID NO.: 1;    nucleotides 39-1346 of SEQ. ID NO.: 1;    nucleotides 39-1262 of SEQ. ID NO.: 1;    nucleotides 99-1346 of SEQ. ID NO.: 1; or    nucleotides 99-1262 of SEQ. ID NO.: 1.    
     
     
         5 . (Cancelled).  
     
     
         6 . (Cancelled).  
     
     
         7 . (Cancelled).  
     
     
         8 . (Cancelled).  
     
     
         9 . Antibody against a polypeptide of  claim 1 , or an epitome thereof.  
     
     
         10 . Antibody according to  claim 9 , characterized in that it is a monoclonal antibody.  
     
     
         11 . Process for detecting polycythaemia vera, characterized in that the polypeptide according to  claim 1  is reacted, in an immunoassay, with one or more antibody(ies) being monoclonal.  
     
     
         12 . Process according to  claim 11 , characterized in that the antibody employed is a polyclonal or monoclonal antibody.  
     
     
         13 . Process for detecting polycythaemia vera, characterized in that the PRV-1 polynucleotide is detected using an RT-PCR method or a blotting method.  
     
     
         14 . Drug for treating polycythaemia vera, characterized in that, in addition to customary excipients, it comprises polyclonal or monoclonal antibodies according to  claim 10 .  
     
     
         15 . Drug, comprising a polypeptide according to  claim 1  and at least one pharmaceutically tolerated excipient.  
     
     
         16 . Drug, comprising a polynucleotide according to  claim 4  and at least one pharmaceutically tolerated excipient.  
     
     
         17 . Use of a polypeptide according to  claim 1  as a growth factor.  
     
     
         18 . Use of polypeptide according to  claim 1  for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.  
     
     
         19 . Use of a polynucelotide according to  claim 4  for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.  
     
     
         20 . Use of a polypeptide according to  claim 1  for treating and/or multiplying endogenous cells and/or established cell lines ex vivo or in vitro.  
     
     
         21 . Kit for detecting polycythaemia vera, comprising at least one polynucleotide according to  claim 4 , or a fragment thereof.  
     
     
         22 . Kit for detecting disturbances of the haematopoietic system, comprising at least one polynucleotide according to  claim 4 , or a fragment thereof.  
     
     
         23 . Kit for detecting the PRV-1 protein according to  claim 21 , characterized in that it is an ELISA test kit.  
     
     
         24 . Kit for detecting polycythaemia vera, comprising at least one polypeptide according to  claim 1 .  
     
     
         25 . Kit for detecting polycythaemia vera, comprising at least one antibody according to  claim 9 .  
     
     
         26 . Kit for detecting polycythaemia vera, comprising at least one antibody according to  claim 10 .  
     
     
         27 . Kit for detecting disturbances of the haematopoietic system, comprising at least one polypeptide according to  claim 1 .  
     
     
         28 . Kit for detecting disturbances of the haematopoietic system, comprising at least one antibody according to  claim 9 .  
     
     
         29 . Kit for detecting disturbances of the haematopoietic system, comprising at least one antibody according to  claim 10.

Join the waitlist — get patent alerts

Track US2004259110A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.